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Executive Summary
This quantitative, non-experimental, retrospective chart review investigated the
possible presence of clinician driven disparities in the care of Black/African American
patients with diabetes at an urban clinic. The study was a response to the Institute of
Medicine’s call to address patient, system, and clinician issues that negatively impact
management of patients with chronic diseases including diabetes. The goal is to
improve patient outcomes using system wide care guidelines to increase success at
meeting the nationally accepted Diabetes 5 (D5) measures.
During a twelve month period, clinician response to elevated low density
lipoproteins (LDLs) was assessed while considering patient preferences, side effects of
medications, economic issues, and patient adherence. Patients were divided into
groups with either government or private insurance and by race/ethnicity. The sample
consisted of 75 individuals, 41 Caucasian, 19 African Americans, and 15 Eastern
Africans.
The study used an unvalidated diabetes chart assessment tool developed by the
researcher. Information regarding other LDL related comorbidities were tracked
including body mass index and hypertension. The study was guided by the social
justice theory and Wagner’s Chronic Care Model.
Findings of the study did not support clinician driven disparities. However, it
was evident there is room for improvement in LDL management of patients in the
study regardless of race or socioeconomic status.
The research makes several recommendations for systems changes to improve
outcomes of diabetes management of all patients at the clinic.
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Chapter 1
Background and Significance of the Study
The Centers for Disease Control (CDC, 2010) estimated 24 million people
in the United States have diabetes. Of these, approximately 18 million people
have been diagnosed with diabetes; 6 million have diabetes but are currently
undiagnosed. Nearly all undiagnosed individuals have Type 2 diabetes. Type 1
diabetes accounts for 5-10% of the disease and occurs mainly in children and
adolescents 18 years and younger. Type 2 diabetes usually occurs in adults, most
commonly diagnosed after 60 years of age, and accounts for 90% to 95% of all
diagnosed cases.
In 2007, uncontrolled diabetes is recorded on death certificates as the 7th
leading cause of death. However, it is estimated the number of patients who die of
diabetes is greatly underreported (CDC, 2007). According to the CDC’s Healthy
People 2010 progress review (2005), deaths from diabetes are two times higher in the
African American population than they are in Caucasians.
All of these numbers are expected to rise as it is estimated the incidence of
diabetes in the United States is increasing to near epidemic proportions with
approximately 1.6 million new cases diagnosed annually in all ethnic groups. Healthy
People 2010, a national initiative, notes that improved data collection and surveillance
systems are, to some degree, factors that are contributing to the increased reported
numbers in patients with diabetes.
Information available on Caucasians adults indicates that 14.9 million (9.8% of
the population) have diagnosed or undiagnosed diabetes. In 2007, sufficient data were
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not available to derive prevalence estimates of both diagnosed and undiagnosed
diabetes for all minority populations. However, available information regarding nonHispanic Blacks in this age group indicated that 3.7 million or 14.7% had diagnosed
and undiagnosed diabetes (Magwood, Zapka, & Jenkins, 2008). Updated information
in a CDC press release dated June 24, 2008 reported “the rate of diagnosed diabetes
was highest among Native Americans and Alaska Natives (16.5 percent). . . . followed
by blacks [sic] (11.8 percent) and Hispanics (10.4 percent), [including Puerto Ricans,
Mexican Americans, and Cubans]. By comparison, the rate for Asian Americans was
7.5 percent with whites [sic] at 6.6 percent “(CDC, 2008, p. 1).
Diabetes can lead to unfortunate and expensive complications including
cardiovascular disease, strokes, blindness, end stage renal disease, neuropathy, erectile
dysfunction, and non-traumatic lower limb amputations. Ethnic minorities, including
African Americans, are disproportionally affected by diabetes and consequently suffer
disproportionately from long term complications of the disease.
Not surprisingly, Barnes et al. (2004) note the cost of health care is four times
greater for patients with diabetes than for individuals without diabetes with $174
billion spent for both direct ($116 billion) and indirect ($58 billion) health care costs.
Direct costs include illness requiring medical care, procedures, medications, insulin, xrays, and surgery. Examples of indirect costs include unnecessary illness, expense,
work loss, premature mortality, and disability.
It has long been recognized that ethnic/racial minorities in the United States
receive suboptimal health care. In 1998, Congress commissioned the Institute of
Medicine (IOM) to examine issues of disparity and implications for patient care,
research, and education. In 1999, the IOM published its Unequal Treatment Report
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which verified the presence of disparities in health care citing patient factors, system
factors, and clinician factors as contributing to the inequity (IOM, 2003). In the report
Crossing the Quality Chasm: 2001, the IOM noted sizable gaps in health care quality
with diabetes as one of 20 priority areas for improvement. The report called for
“substantial improvements in six major aims–that health care be safe, effective,
patient-centered, timely, efficient, and equitable” (p. 11). Healthy People 2010 builds
on health care information from the past twenty years and contains 467 objectives for
improved health care (including care of patients with diabetes) for the years 20002010. Healthy People 2010 delineates two overarching goals—to increase quality and
years of healthy life and to eliminate health care disparities (HHS, 2005).
The United States is making dramatic improvements in overall health and life
expectancy of its citizens including those with diabetes. For example, the adjusted rate
of diabetes related deaths in all patients has dropped from 7.6 per 1000 in 2003 to
3.0% per 100,000 in 2009 (CDC, 2009). Despite this improvement, national data
continue to indicate that minority Americans have poorer health outcomes from
preventable and treatable diseases (including diabetes) when compared to Caucasians.
According to Bach et al., when treatment disparities are eliminated, disparities in
health outcomes are substantially attenuated or absent (2002).
On a local level, the Minnesota Department of Human Services and Minnesota
Community Measures (MNCM) have adopted the nine nationally accepted health care
measures of care, one of which includes optimal diabetes care. For the last two years,
MNCM has compiled a report comparing the performance of clinics and medical
groups within the state on these measures. The patients are divided into two groups:
residents of Minnesota whose health care is covered under government insurance, the
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Minnesota Health Care Programs (MHCP), and those who have private, purchased
(other) health care insurance. A disproportionately higher number of individuals from
ethnic/racial minorities in Minnesota are from a population with a lower
socioeconomic status (SES) and are insured through government plans (Minnesota
Community Measurement, 2009, Executive Summary). Statistics regarding type of
insurance are important because the prevalence of obesity (a risk factor for diabetes)
and diabetes are inversely related to socioeconomic status (Betancourt & Maina,
2004); type of insurance is often used as a measure of SES. In addition, these authors
found disparities exist even in insured minorities. This is in agreement with the IOM
report (2003) indicating racial and ethnic minorities receive lower quality of health
care even when medical insurance and income levels are the same.
The 2008 Health Care Disparities Report for Minnesota Health Care Program
determined that, using the IOM’s quality measures, “. . . performance in achieving
high quality care was significantly lower at both the statewide and medical group
levels for MHCP compared with Other Purchasers. . . .(although) gaps in performance
between MHCP and Other Purchasers have narrowed for all measures. . . . (including)
optimal diabetes care” (mnhealthscores.org, 2009, p. 5). The D5 is a nationally
accepted measure of adequate diabetes care and includes reaching the following five
measures: 1) hemoglobin A1C below 7%; 2) blood pressure below 130/80; 3) low
density lipoprotein below 100; 4) use of one aspirin daily and 5) nonsmoking status.
Statewide, 7.8% of diabetic patients with MHCP have reached a D5; 13.4% of patients
with private (Other) insurance have reached a D5 (Minnesota Community
Measurements, 2009).
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Quality measures at the large health care system where this study took place
have improved in several MNCM quality measures and have shown some, but not
optimal, improvement in the area of diabetes care. According to MNCM, this care
system ranks sixth out of the eight major health care systems in the Twin Cities area in
percentage of patients who have achieved a D5 score (Minnesota Health Scores,
2008). The system’s goal in 2009 for D5 scores (with A1C of below7.0%) was 20%.
The percentage of D5s across the system was 14% in 2008 and 19% as of March,
2009. The average D5 among the 18 primary care clinics was 22.8%. The urban
clinic where the study took place has a high percentage of individuals with
government insurance and consistently has the lowest percent of patients with a D5
reaching only 13% at the end of March 2009 (health care system statistics, 2009).
The researcher met with a leading endocrinologist at the health care system to
discuss parameters of the study. The number of patients with elevated hemoglobin
A1C levels and elevated low density lipoprotein, both of which are outcome measures
of the D5, varied from month to month at the clinic where the study took place.
Treatment of elevated blood glucose involves considerably more options than those to
treat elevated lipoproteins; for these reasons this study tracked clinician response to
LDL values when investigating the possibility of clinician driven disparities.
The clinic is located in an area where there is a large Eastern African
population. The endocrinologist suggested the researcher also separate patients from
Eastern Africa from those patients who indicated race/ethnicity as Black/African
American to look for any differences within the Eastern African population related to
diabetes care.
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The researcher is a certified nurse practitioner and clinical practice director
(CPD) at this large urban clinic. As a CPD, one of the researcher’s responsibilities is
to work toward improved patient care and outcomes, including those of patients with
diabetes. Optimal diabetes care measures at the clinic have consistently been the
lowest when compared to all other primary care clinics within this health care system
and suggest ethnic/racial disparities in care. For example, 34.5% of Caucasian and
12% of Black/African Americans had LDLs under control throughout this study (see
Appendix A, sample size, inclusion and exclusion criteria). During meetings related to
improving diabetes care outcome measures, clinicians at the clinic most often cite
patient issues as an explanation of suboptimal outcome indicators. This explanation
coincides with the findings by Sequist, Ayanian, Marshall, Fitzmaurice, and Safran
(2008) who noted that clinicians were more likely to perceive patient factors than
clinician or systems factors as contributing to less than optimal patient care outcomes.
Improved diabetes care outcomes should lead to improved health of patients of
the system and would decrease the number, and therefore, cost of care of individuals
who experience long term complications of diabetes. The cost of patient care may
decrease as, according to Stewart et al. (2000), common ground in clinician-patient
interactions is associated with “. . . better (patient) recovery . . . . and (appropriately)
fewer diagnostic tests and referrals” (p. 796).
In addition to improved patient outcomes, this health care system could benefit
from financial incentives offered by third party payers. These payers are providing
substantial bonuses to health care systems who meet the benchmark goals of the D5 in
the care of diabetes patients. According to the director of health support for this health
care system (personal communication, July 25, 2009), one internal medicine site
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within the system is currently participating in a pilot program with five payers, the
majority of which provide $50 per patient per month to manage care of patients with
diabetes who do not meet the D5 benchmarks. Two of these payers have provided the
health care system with a grant to support this pilot project. According to information
presented at the July 7, 2009 clinical practice directors and clinician managers
meeting, “(This health care system) is at risk for more than $1 million in pay for
performance withhold from our payers” In this statement, the presenter was referring
to reimbursements from third party payers to health care systems that reach benchmark
goals of patient care thereby.decreasing cost of care to enrollees in the managed care
plan
Research Question
Are there clinician driven disparities in the care of Black/African American patients
with diabetes?
Hypothesis:
There are clinician driven disparities in the care of Black/African American
patients with diabetes when compared to care of Caucasians.
There is a need for system change if the low density level of
Black/African American patients is out of control more often than those of Caucasians
and/or if there are differences in the number of actions clinicians take to address
elevated LDL levels in patients of different race/ethnicity.
Challenges of the Study
This study found no clinician driven disparities. Examining this issue was
important since most clinicians agree health care disparities occur at the national or
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state level and even within the community where the clinician practices but do not feel
disparities occur with patients under his/her care (Sequist et al. 2008).
Clinicians often report there is not enough time for optimal diabetes care and
that they are being asked to provide more care with the same or fewer resources
(Bodenheimer, Wagner, & Grumbach, 2002). When clinicians are under increased
stress and time pressures there is a subconscious tendency to categorize or stereotype
beliefs and expectations based on ethnicity in an effort to simplify and shortcut
decision making (Betancourt & Maina, 2004).
This study depends on race/ethnicity as supplied by the patient when
registering at the clinic for an initial appointment. The clinic manager estimates 95%
of patients register over the phone and are asked about their ethnicity using a standard
race/ethnicity selection form. The remainder of patients register at the front desk; on
some occasions and for various reasons, staff find it necessary to make reasonable
guesses regarding patient ethnic/racial background. Information regarding preferred
patient language and need for interpreter are also gathered. While this is an imperfect
process, the efforts of this health care system are more forward-thinking than the many
institutions which have not yet begun to collect any information regarding
race/ethnicity making it impossible to understand and track progress toward improved
care and outcomes of minority populations (Betancourt & Maina, 2004).
Project Objectives
The purpose of the study was to determine if clinician driven disparities exist
in the care of Black/African American patients with diabetes at this large urban clinic.
Data collection was performed to determine if both Caucasian and Black/African
American patients with diabetes received equal and appropriate care in management of
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LDL levels. The study tracked appropriate use of lifestyle coaching and the use of
statins as outlined in the organization’s standards of care. Patient preferences,
economic challenges, and patient response to clinician recommendations were
monitored since any of these issues may affect the clinician’s ability to move forward
in interventions to improve care outcomes. Analysis attempted to determine if levels
of care differ related to race/ethnicity and/or type of insurance.
Social Justice Theory
The ultimate goal of this project is to improve the care of all patients with
diabetes through equitable care, improved management of diabetes, avoidance of
complications of diabetes, and premature deaths. It is expected improved care of
ethnically/racially diverse patients will also have a positive impact on care of all
patients with diabetes, including Caucasians. An understanding of clinician issues
related to inequities in care is necessary before action can be taken to address the
problem at clinic, system, community, and national levels. Actions toward inequities
in care are appropriately addressed through the lens of social justice.
Social justice has six dimensions: health, personal security, reasoning, respect
of others, attachment, and self-determination (Mathis, 2007). It is the principle of
moral rightness and equity as applied to individuals living together in communities
and sees each individual as an equal part of who we are as a society. In her
presentation in 2008, Sister Amata Miller explained social justice attends to the needs
of the individual, looks for answers to inequities and calls for a social response
(action) to address a problem. It demands fair and impartial treatment of others and
conformity to moral rightness in attitude and action.
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Social justice refers to institutions in society that aspire to fairness between two
individuals (or between an individual and a group) and holds the government
responsible for equitable distribution of the goods of society. Social justice requires
skills of “inspiring, working with, and organizing others to accomplish together a work
of justice . . . . it aims at the good of the city, not at the good of one agent only
“(Novak, 2000, p. 2). Equality in health care means provision of care that does not
differ in quality because of ethnicity or socioeconomic status and is included as a goal
of and commitment to equity in health care outcomes in the 21st century (Crossing the
Quality Chasm, 2001).
In Unequal Treatment (2003), health care is determined to be a resource, a
social good, tied to social justice and quality of life for individuals and groups. In his
work, Distrust, Social Justice, and Health Care (1999), McGary notes most
individuals in the United States view health care as a “primary good” that every
rational person is presumed to want. The author refers to the writings of Dr. Rawlings,
a leading political philosopher, on the subject of social justice. “Rawlings argues that
the allocation of these goods is subject to the contraints of justice . . . . (and contends)
. . . . that the least-advantaged members of society, as measured by their possession of
the primary goods, should be the gauge by which we judge the justness of the basic
structure of society” (p. 236). McGary sees justice as a first virtue of social
institutions which are responsible for establishment of rules of society. Where
injustice is seen, the state has a mandate to take action to eliminate or mitigate the
inequality. The author refers to the resulting general distrust by Blacks/African
Americans of all public institutions (and particularly the health care system) based, in
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part, on the gross injustices and breaches of trust by the medical community toward
minorities and especially African Americans.
In her compelling book, Medical Apartheid, Washington (2006) writes of the
long history of injustices, particularly medical experimentation, perpetrated upon
minority individuals extending back to at least the eighteenth century as “more than a
historical fact. Although less rife, it remains a contemporary reality, and an everpresent possibility” (p.386). Washington acknowledges that medical research
involving minorities today is much safer and, in fact, necessary to address health care
issues, particularly those that affect Blacks/African Americans in greater numbers or
level of severity. Washington encourages African Americans to welcome and
participate in medical research while remaining wary of research abuses. She cautions
that “Both the federal government and private corporations have devised large-scale
research abuses that range from radiation experiments to biological-weapons
development. This medical ill-usage has not strictly paralleled scientific knowledge:
Rather, it has mirrored the larger American cultural beliefs as well as politics and
economic trends “(p. 385).
McGary (1999) notes the perception of unfair treatment by the health care
system does not mean the inequity actually is occurring. However, McGary proports
the health care system has a responsibility to acknowledge the history of this distrust
and correct erroneous perceptions. This is good counsel for the government given this
nation’s long history of laws and policies that condoned discrimination until the Civil
Rights Acts of 1964 and 1968. Policymakers have long known of disparities in health
care and have established eliminating health care disparities as a priority. It is
important for researchers in health care to explain the value of ethical research and
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changes in health care that focus on the ethnically or racially diverse. These special
efforts, without being excessive, may reestablish confidence in these basic institutions
of society.
Nursing codes of ethics “identify standards of practice, detail provision of
particular services, and address fiduciary relationships that are essential hallmarks of
any profession (Salladay, 2008). These codes hold the nurse accountable as an
individual who has a special relationship of trust, confidence, or responsibility to
others. As a guide for action based on social values and needs, the Code of Ethics for
Nurses with Interpretive Statements (2008) assigns nurses the fundamental
responsibility for promotion and restoration of health in care of patients and
communities without regard of race or economic status. Crigger (2008) notes nurses
are committed to justice in health care and are called to be responsive to differences in
health resources and resource distribution. Nurses need to raise the moral sensibility
of unfairness and are encouraged to engage in social justice at local, national, and
international levels. The author states: “Nursing is potentially a very powerful
international discipline, a from below agency, that can impact on social, economic and
political climate of the world” (p. 21).
Nurse practitioners (NPs), in particular, have a mandate and are uniquely
positioned to address issues of social justice while working to improve the health of
others. In their article, Examining the Potential of Nurse Practitioners from a Critical
Social Justice Perspective, Browne and Tarlier (2008) note “. . . we have come to
recognize the ‘value added’ component of NP practice – namely, the social justice
aspects of the role in the context of illness treatment, health promotion and prevention
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services “(p. 89). Nurse practitioners must advocate for changes that are at the root of
practices that perpetuate inequities.
This system change project is based on principles of social justice and is the
first step in determining the need for action aimed toward the reduction of health care
disparities of patients within the clinic and throughout the health care system.
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Chapter 2
Theoretical Framework
Wagner’s Chronic Care Model is the theory supporting this system change
project. Dr. Wagner proposes a reorganization and redesign of a different type of care
system more tailored to the needs of patients with chronic illnesses. Wagner includes
six interrelated components of care that guide improved management of patients with
chronic disease. These six components are self-management support, clinical
information systems, delivery systems redesign, decision support, health care
organization, and community resources. Decision support includes the use of evidence
based practice clinical guidelines into patient care of individuals with chronic diseases
(Bodenheimer, Wagner, & Grumbach, 2002a). Wagner’s model strives for improved
health care outcomes as the result of productive interactions between an informed,
activated patient and a prepared, proactive practice team.
The health care system where this study took place regularly disseminates
information regarding updated practice guidelines for the care of patients with
diabetes. A diabetes registry is updated and distributed monthly to all clinicians
involved in primary care of patients with diabetes. The registry includes information
regarding current measures of each patient’s progress toward a D5. During the time of
this study, each clinician/nurse team worked together to manage the registries although
with varied success. In his Chronic Care Model, Wagner recommends that one
individual at each clinic be assigned the responsibility of working the registries.
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Literature Review
Background
As stated earlier, when the IOM published its Unequal Treatment Report
(verifying disparities in health care of minorities), patient factors, system factors, and
clinician factors were identified as contributing to the disparities (2003).
Patient issues.
Healthy People 2010 (2005) cites many patient issues that may contribute to
health care disparities in patients with diabetes. These include but are not limited to
“Westernization” of diet (increased fats and processed foods), demographic changes,
decreased physical activity, genetics, socioeconomic status, level of patient
knowledge, and cultural and community traditions. Another proposed patient factor is
the belief that African Americans have a stronger sense of the present and a fatalistic
view of their diabetes believing the disease and associated complications are inevitable
and unpreventable (Barnes et al. 2004). Dagago, Funnell, and Davidson (2006) found
that, as a group, African American individuals are usually aware of the increased
incidence of diabetes in the African American population but have a lower level of
understanding of the complications of diabetes.
Adverse social determinants also contribute to patient factors. These include a
lower level of education, inadequate or unsafe housing, racism, and living in close
proximity to environmental hazards (Betancourt & Maina, 2004). Dovidio et al.
(2008) noted unequal distribution of medical services and the associated poor access to
health care as two system factors that disproportionately and negatively affect the
health care of Black/African American patients. Although there is a belief that
ethnic/racial minorities show poor adherence to treatment regimens, Egede and
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Dagago (2005) note there is no evidence for ethnic nonadherence to treatment plans
with the exception of self blood glucose monitoring (SBGM). However, almost all
patients with diabetes monitor their blood glucose less frequently than recommended
with 18% of African Americans and 30% of Caucasian patients testing at minimal
recommendations. These authors recommend clinicians not assume lack of adherence
to a treatment plan until the patient reports that this is actually the case.
Another patient issue, some aspects of which are intertwined with systems
issues, is lack of health care insurance in the minority population. Betancourt and
Maina (2004) reported a disproportionate number of minorities are uninsured: 20% of
African Americans are uninsured as compared to only 11% of Caucasian patients. In
addition, diabetes care and outcomes can be affected by insurance issues when
clinicians make incorrect assumptions regarding the person’s insurance status and
likelihood of adherence to a treatment plan. Kirk et al (2005) note clinicians may
make incorrect assumptions regarding minority patients’ insurance coverage which
can adversely affect other care decisions including additional testing and referrals.
Lurie et al. (2005) came to that same conclusion when researching disparities in
referrals among cardiologist noting that “. . . referral decisions were often based on
incorrect assumptions about patient insurance status. In other words, the physician
often assumed that the patient was uninsured when this was, in fact, not the case” (p.
1269).
Systems issues.
System issues refer to the manner in which health care is structured at a systems level
and may affect patient ability or willingness to seek or continue with health care. Historic
and contemporary inequalities have led to a persistent wariness between the medical
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community and Black African/ American patients which can affect the climate of health care
interactions and health care outcomes. Betancourt and Maina (2004) reported 65% of African
American patients are afraid of being treated unfairly at future health care visits while only
22% of Caucasians individuals have that same concern. This distrust between the Black/
African American population and clinician-researchers continues to contribute to the
underrepresentation of minorities in contemporary health care research. According to Clark
(2009), “. . . although African Americans make up only 13% of the United States population,
they account for almost half of the estimated number of HIV/AIDS diagnoses made during
2006“ (p.123). However, non-Hispanic Blacks and Hispanic patients were less likely to
participate in trials than Caucasians and, therefore, less likely to receive experimental
medications. These authors note the work of J. Merz who wrote that underrepresentation in
clinical trials “leads to results that do not account for a host of factors. . . that could have a
huge impact on how well new drugs do in the real world” (p. 1).
As noted by the IOM in Shaping the Future for Health (2001), other system problems
include language barriers, fragmented health care systems (where minorities are enrolled in
government programs, often with greater limitations on health care expenditures), and
incentives to clinicians to limit services. Even when minorities and Caucasians have the same
type of insurance, the location of and/or lack of access to care for these potentially expensive
patients can be a barrier.
Clinician issues.
The third factor noted by the IOM as contributing to health care disparities is clinician
issues. According to Larme and Pugh (1998), medicine is driven by symptoms. These authors
address the appeal of treating acute illnesses while chronic care (with few or no immediate
symptoms) requires efforts toward preventing complications that may not occur for many
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years. It is easier and more gratifying to treat and provide relief to those who are experiencing
symptoms at the time of the visit. The authors contend the emphasis of medical education and
continued medication education is more often focused on acute problems and illnesses and is
less effective in imparting information related toward improved chronic disease management.
In addition, the authors note the treatment of diabetes is labor intensive and time consuming.
Clinicians are aware that SBGM causes pain to patients instead of immediate alleviation of
symptoms. Clinicians are slow to adopt standards of care and have a negative opinion of the
flow sheets used to track care measures. The authors note that “Primary care providers have
the most negative attitudes about diabetes, yet they provide 80% of all office visits for
diabetes mellitus “(p. 1391).
Bodenheimer, Wagner, and Grumbach (2002a) refer to the “tyranny of the urgent”.
“Frequently, the acute symptoms and concerns of the patient crowd out the less urgent need to
bring chronic illness under optimal management. . . . patients are not adequately taught to care
for their own illnesses. . . . Too often, caring for chronic illness features an uninformed
passive patient interacting with an unprepared practice team, resulting in frustrating,
inadequate encounters” (pp. 1-2). These authors recommend creation of practice teams that
integrate evidence-based clinicial practice guidelines into care of patients with chronic
illnesses.
Clinician inertia, the recognition of a problem but failure to act, has been
attributed to an overestimation of care provided, the use of “soft” reasons to delay
increased use of medications, and/or a lack of focus on therapeutic goals (Phillips et
al., 2001). For example, a clinician fails to advance therapy in a nonadherent,
morbidly obese patient who has had time and expressed intent to improve glycemic
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control and eating habits but whose diabetes remains uncontrolled and who has not
gone forward with changes in eating habits.
In addition, clinicians feel there is not enough time for diabetes care. Bodenheimer,
Wagner, and Grumbach (2002b) noted clinicians often had only ten minutes of face-to-face
time with the patient, five of which was spent on diabetes management. Under these
circumstances, although 65% of the patients had an average HgbA1C of 8.9%, therapy was
intensified only 15% of the time. Interestingly, there was no difference in quality of care
between high and low volume clinicians.
In 2002b, these same authors describe the “hamster syndrome” in health care, i.e. the
push to work harder with the same or, in some cases, fewer resources. This syndrome leads to
use of the conditioning phenomenon which involves assigning individuals to a group based on
race, gender, or age and then applying group characteristics to individuals. This conditioning
phenomenon is used by all human beings, subconsciously and automatically, to simplify
decision making and lessen cognitive effort. Individuals are more likely to resort to this type
of behavior when stressed as is often the case during a rushed health care visit. Some
clinicians, however, have an overly positive view of the quality of care provided even under
the above noted circumstances (Bodenheimer, Wagner, & Grumbach, 2002b). In addition,
many patient behaviors are related to less apparent socioeconomic factors (e.g. poverty) and
not race, ethnicity, or cultural traditions (Betancourt & Maina, 2004).
The “Not Me” Phenomenon is the belief that racial disparities occur in health care but
not in the individual clinician’s practice. “. . . Whereas the majority of primary-care clinicians
support the collection of patient race and ethnicity data, only a minority report the presence of
racial disparities in diabetes care among patients they personally treat" (Sequist et al. 2008, p.
683). These authors report that 88% of primary care providers nationally agree that disparities
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occur but only 40% believe differences in care of minority patients would be noted in the
clinician’s own patients/clinic. A meta-analysis of 35 studies compiled by Kirk et al. (2005)
cited data indicating “The major ethnic differences (in patients with diabetes) reported were
lower rates of eye examination, influenza vaccination, and lipoprotein testing among
Hispanics and African Americans than among non-Hispanic whites” (p. 349).
Definition of Terms
Health care disparities.
Braveman (2006) defines health disparities as “a difference in which
disadvantaged social groups---such as the poor, racial/ethnic minorities, women, or
other groups who have persistently experienced social disadvantage or discrimination---systematically experience worse health or greater health risks than more advantaged
social groups” (p. 167).
Low density lipoproteins.
Cholesterol is a fat-like substance containing both lipids and proteins.
Cholesterol travels in the blood and is present in cell membranes. The three major
classifications of lipoproteins measured in fasting serum are high density lipoproteins
(HDL), low density lipoproteins (LDL), and very low density lipoproteins (VLDL).
Sixty to seventy percent of cholesterol is made up of LDL which are the major
atherogenic lipoproteins and the primary target of cholesterol-lowering therapies.
Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower
cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a
central role in the production of cholesterol in the liver. Although LDL continues to
receive primary attention, growing evidence indicates that VLDL and HDL also play
an important role in atherogenesis. Elevated HDL levels are inversely related to risk
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of coronary heart disease. Low HDL levels often reflect the presence of atherogenic
factors. VLDLs are precursors of LDL; some forms of VLDL appear to promote
atherogenesis, similar to LDLs.
According to the National Institutes of Health’s ATP Panel III Final Report
(2001), “Persons with type 2 diabetes have a 10-year risk for major coronary events
(myocardial infarction and CHD [coronary heart disease] that approximates the risk in
CHD patients without diabetes. . . . Thus type 2 diabetes constitutes a CHD risk
equivalent” (p. II-53, National Institutes of Health, 2001.) In patients with diabetes,
aggressive cholesterol-lowering therapy still leaves absolute CHD rates far above
those in low-risk populations (p. II-4.) For this reason, treatment of LDLs in patients
with type 2 diabetes should follow recommendations for persons with established
CHD. According to the Institute for Clinical Systems Improvement (ICSI, 2008),
“The goal (for patients with diabetes) with CAD [coronary artery disease] is less than
70 mg/dL. . . . even [in those patients] with a baseline LDL of less than 100 mg/dL”
(p. 26). The NIH advises:
Persons with LDL cholesterol ≥ 130 mg/dL generally require a statin drug to
achieve LDL cholesterol < 100. Therefore, a statin should be initiated
simultanteously with TLC [therapeutic lifestyle changes] and maximal control
of other risk factors. . . .[those] with LDL cholesterol ≥ 130 mg/dL generally
will require an LDL-lowering drug to achieve LDL cholesterol < 100 mg/dL.
(2001, p. IV-2).
This report maintains a goal of LDL under 100 in individuals with diabetes but
acknowledges there are differing recommendations regarding treatment of LDL in
individuals whose level is between 100-129 mg/dL. Some authorities recommend
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initiation of statins if TLC do not bring the LDL level to < 100; others recommend use
of drugs that modify other lipoprotein factors (High [HDL] and very low density
lipoproteins [VDLD], and triglycerides) e.g. nicotinic acid and fibrates. Still other
sources allow the clinician to use clinical judgement in the decision to withhold drug
treatment in these individuals (NIH, 2001.) The care system where this study took
place, as well as MNCM holds to an LDL of < 100 in individuals with diabetes; an
LDL at this level remains the desired outcome measure in determination of the D5.
Individuals under 18 or over 75 and those treated for active cancer are not included in
the health care system’s diabetes registry.
The health care system where this study took place includes lipid testing as part
of diabetes standing orders (see Table 1).
Table 1
Diabetes Standing Orders
Lipid testing
Lipid Testing
If

Lab Test

Frequency

LDL ≥ 100

Chol Fx/AST

Within 6-12 weeks

No Lipid Med

Chol Fx

Within 12 months

Stable Lipid Med

Chol Fx/AST

Within 12 months
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Chapter 3
Methodology
Study design.
This study was a quantitative, non-experimental, retrospective chart review.
The study used lab values and office visits of patients seen within an 18 month time
frame between January 1, 2008 and June 30, 2009. Within this 18 month window, the
goal was to have at least twelve consecutive months of data on each patient, beginning
with the most recent primary care appointment between January 1, 2009 and June 30,
2009 and working back in time through the medical records.
Study sample.
The target population was patients ages 18-75 inclusive with permanent Last
Word addresses in Minnesota or Wisconsin, who have been seen in primary care for
an outpatient clinic visit at least three times in the last 12 months, carried an ICD-9CM diabetes mellitus (250.xx) code on their problem list, and whose primary care
clinician and diabetes clinician practice within the internal medicine department at the
clinic.
Inclusion/Exclusion criteria.
In order to be included in the study, the patient had to have been seen at least
three times within an 18 month window beginning January 1, 2008 and ending June
30, 2009. This initial query yielded a list of 417 patients, 235 Caucasians and 182
Black/African Americans. The focus of this study was to investigate clinician
response to individuals with LDLs out of control. For this reason, 103 patients had
LDL values that were under control during the entire time frame of the study and so
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were excluded. Of this sample, 34.5% were Caucasian and 12.1% were Black/African
American. (Appendix A).
There was inadequate lab data on 57 Caucasians (24.3%) and 57 Black/African
Americans (31.3%). A total of 12 patients were eliminated due to an inadequate
number of office visits.
This study investigated possible differences in care between African
Americans and individuals who came to the United States from Eastern Africa. In
order to make as accurate a determination as possible, a review of the medical record
was completed on all individuals who identified themselves as Black/African
American. Individuals whose demographic information indicated the need for an
interpreter of a language spoken in Eastern African (e.g. Somali) or whose country of
origin was dictated in the medical record as being from an Eastern African country
were accepted as Eastern African and included in the study (see Appendix B for
Eastern African countries and languages). There were 31 individuals who indicated
their race/ethnicity as being Black/African American but whose medical record gave
no information as to whether the patient was of African American or Eastern African
descent and so were excluded. Fifteen patients whose medical record indicated
country of origin as one on the continent of Africa but not from Eastern Africa (as
defined by the CDC) or who were from other parts of the world were excluded.
This study used type of insurance as an indicator of socioeconomic status.
Thirty six patients were self-pay or had both government and private insurance and
were excluded from the study (see Appendix C for list of government and private
insurances). Because this study included individuals ages 18-75, it is likely some
patients excluded from the study because they had both government and private
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insurance were individuals 65 and over who had Medicare and a privately purchased
supplemental insurance. Individuals who were missing lab data or had not been seen
three times during the time frame of the study (114) were excluded.
From the original query of 417 patients, 194 (82.6%) Caucasians and 148
(81.3%) Black/African Americans were excluded. The final sample of 75 patients
included 41 Caucasians and 34 Black/African Americans. The researcher was able to
determine that 15 of the 34 Black/African American sample were of Eastern African
descent.
Research tool.
The diabetes chart audit tool (Appendix D) was used to monitor actions taken
by clinicians during and between office visits related to LDL testing to determine the
presence or absence of health care disparities. Chart review included a manual search
for demographic and insurance information, review of office visit dictations, lab order
forms, lab letters, telephone calls, pharmacy records, and health care records from
other health care facilities imported into the patient medical record.
The tool monitored sequencing and recommendations of lifestyle coaching,
starting, changing, increasing, or discontinuation of a statin, and clinician
recommendation to schedule a follow up appointment and/or lab draw. Information
regarding the number of patients who expressed concern regarding the cost of
medication and clinician response to this information was entered on the tool.
Because untoward side effects of statins could influence clinician actions this
information was also tracked.
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The tool indicated the percentage of clinicians taking action for those patients
whose LDLs were out of control during the time periods of the study. Information
from the tool was used to define four groups of patients:
1) Those whose LDL was under control and taking a statin.
2) Those whose LDL was under control and not taking a statin.
3) Those whose LDL was not under control and taking a statin.
4) Those whose LDL was not under control and not taking a statin.
Each of these groups were then divided by race/ethnicity. Tests for differences
in percentage of patients with appropriate actions taken by clinicians and differences
in proportions based on race were reported.
Body mass index.
Obesity is a risk factor for many chronic diseases including diabetes and
hypercholesterolemia. The body mass index (BMI) is used to define normal weight,
overweight, and obesity. Although the level of risk associated with BMI varies slightly
depending on race/ethnicity, a person is considered overweight if the BMI is above
24.9 and obese if the BMI is 30 or above.
Lifestyle changes.
Lifestyle changes (modifications of habits or patterns) are often recommended
as a first line therapy for patients whose LDL is out of control. Patients may request a
trial of diet and exercise changes before starting on a statin. These changes are a
mainstay of LDL management and, depending on the degree of LDL elevation, may
prevent the need for statins.
Complementary and alternative medicines.
The tool monitored patient preference for use of complementary and
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alternative medicines (CAM) before being started on a statin. Patient decision to try a
CAM is tracked since this is a patient decision and does not reflect clinician failure to
respond to an elevated LDL value.
CAM is a term currently accepted by the National Institutes of Health to
describe alternative treatments used in place of or in tandem with pharmaceuticals
prescribed by Western medicine to promote health or treat illness. Many patients see a
combination of CAM and conventional medicine as the optimal approach to their
health care particularly when neither approach is viewed in a hierarchal manner.
In their 2007 qualitative study of 37 regular users of IM, McCaffrey, Pugh, and
O’Connor noted more than one-third of Americans preferred to use CAM or
integrative medicine approaches for their health care needs. The participants in their
study emphasized the centrality of the patient-clinician relationship “. . .[in which
physicians are viewed] as guides rather than commanders “(p. 1500). In 2004, a report
released by the National Center for Complementary and Alternative Medicine
(NCCAM) and the National Center for Health Statistics (NCHS) showed that 36% of
American adults were using some form of CAM (Vogel et al., 2005, p. 186). In his
presentation on 11/18/2009, Sash listed plant stanol/sterols, omega-3 (found in oily
fish), flax seed, soluble or viscous fiber, antioxidants, and flavonoids as CAMs that
have been shown to reduce LDL levels.
Patient preference.
Information regarding patient preference was gathered in the chart review tool.
Patient preference has a direct impact on options available to a clinician in
management of LDLs.
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Goff, Mazor, Meterko, Dodd, and Sabin (2007) state an estimated 20-50% of
patients do not take medications as prescribed noting participant beliefs and
preferences about medication prescribing as contributing factors. These beliefs and
preferences “. . . encompassed 3 major areas: patient-doctor relationships, outside
influences, and professional expertise. . . . [and included] participants’ concerns about
the pharmaceutical industry’s influence on doctors’ prescribing practices and belief
that there is a clear ‘best’ medication for most health problems "(p. 236).
In their work exploring the phenomenon of saying “no” to recommendations of
healthcare providers, Michaels, McEwen, and McArthur (2008) compared patient and
professional cultures and their differing approaches to starting medications. These
authors note that, for some individuals, health care is needed only when symptoms
directly impact the everyday experience. A patient symptom based approach to
diabetes and LDL management is one of the clinical challenges in treatment of chronic
disease. Chronic disease management requires convincing the patient to control their
illness become developing symptoms of the long term or fatal complications of poorly
controlled diabetes or LDLs.
The IOM (2001) calls for patient care based on best scientific knowledge
while allowing for patient control. The Institute notes that in order to meet both of
these IOM recommendations, evidence-based practice requires and relies upon
evidence-based individual decision making which can only be learned by listening to
the client’s health stories, values, and beliefs.
Entwistle, Carter, Crubb, and McCaffery acknowledge the value of patient
autonomy but caution that “. . .many health care practices can affect autonomy by
virtue of their effects not only on patients’ treatment preferences and choices, but also
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on their self-identities, self-evaluations and capabilities for autonomy” (2010, p. 741).
The authors agree patients should be offered options, allowed and enabled to make
voluntary choices but note discussions related to autonomy rarely address
implementation of choices and required lifestyle changes. “Patients may feel
abandoned rather than autonomous if their clinicians refuse to do more than inform
them about options and insist they choose. . . . clinician interactions should support
the autonomy of patients. . . by helping (patients) form, maintain or re-establish selfidentifies that they are comfortable with, and to deal with emotions and social stigma
(of disease)” (p. 742).
Ethical Considerations
It is necessary to verify clinician driven disparities before moving forward to
address clinician driven disparities in provision of health care to those from lower
socio-economic backgrounds and/or of Black/African American ethnicity. If clinician
driven disparities are evident, the information must be disseminated in a sensitive and
non-threatening manner. In order to maintain anonymity, information on clinicians
will be presented as a group. The prinicipal investigator and the individual who
completed data entry completed a required on-line educational course regarding ethics
in research. Any information identifying the patient were kept locked in a drawer
unless being used by the researcher or research assistant. A list with the patient’s
medical record and research number were also kept in a restricted access on line
computer folder.
Support From Site
The researcher was invited to a meeting of the health care system’s council of
investigators to discuss and receive input regarding this study. The administration of
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the health care system allowed the principal investigator full access to the medical
records of any patients seen at the clinic with a diagnosis of 250.xx and to insurance
information, outcome data, and initiatives related to improved diabetes care within the
health care system. Two clinicians within the health care system agreed to serve as
site mentor and were readily available to the principal investigator.
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Chapter 4
Data Analysis
This study examined whether the percentage of clinicians following the
protocol for controlling LDL levels differed among all included ethnic groups and
between those with public or private insurance. Assuming 50% of clinicians treating
Caucasians follow the LDL treatment protocols, and 40% of clinicians treating the
Black/African American population follow the protocol with 100 patients in each
racial group, for a one-sided test with a level of significance alpha=0.05, there was
36% power to detect a 10% (e.g. 50-40%) difference, 63% power to detect a 15% (e.g.
55-40%) difference, and 86% power to detect a 20% (e.g.60-40%) difference. Stata
version 10 was the statistical software used to analyze the data.
Description of the sample.
Demographic characteristics.
Over 50% of the sample of 75 patients were Caucasian, 25% were African
American, and 20% were East African (Appendix E). Just over a third (37%) of the
sample was women with a large majority (63%) of African Americans being female.
There were more African American females in the study (63.2%) than Caucasians or
Eastern Africans.
Caucasians were the most likely to be married (42%) and to have private insurance
(73.2%). Across all racial groups, patients were typically in their mid-50s.
Private or public health insurance
Insurance type of those individuals in the study closely matched insurance
coverage of the patient population of all individuals who are patients at the clinic.
Clinic-wide, 41% of patients have government insurance; 59% have private insurance
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or are self pay (personal communication, finance director, September, 2010). The
percentage of patients in the study with government insurance was 38.7% (see
Appendix F for demographic characteristics by payer) As noted on Appendix E, a
significantly larger percentage (73.2%) of Caucasian patients had private insurance
than did African Americans (47.4%) and East Africans (46.7%).
BMI/obesity.
The average BMI in 2008 and 2009 was 33.7 and was nearly the same between
Caucasions and African Americans (Appendix G). The BMI of Eastern Africans
(27.3) was significantly lower than African Americans (35) in both 2008 and 2009.
As a group, Eastern Africans had the lowest BMIs but some of the highest LDLs.
As noted on Appendix H, females were more likely to be morbidly obese than
males. Patients whose BMI was below 25 had the highest LDL (148) compared to
those whose BMIs were over 25 or 30+. This statistic may reflect lower BMIs of
Eastern African patients although the sample size of Eastern Africans is quite small.
Lifestyle changes.
At any point in time, 50% of patients whose LDLs were out of control wanted
to try lifestyle changes. More Caucasians and African Americans than Eastern
Africans wanted to try this approach to LDL management. The small number (1) of
Eastern Africans who preferred to try lifestyle changes (16.7%) brought down the
sample size of all patients who wanted to try lifestyle changes (see Appendix I, actions
taken during the year given baseline status on LDLs and medications).
The primary focus of information presented on Appendix I is on those
individuals whose LDLs were out of control. It is important to understand these
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groups can go in and out of control at any time during this study, i.e. the information
in this study was not presented in a linear fashion.
Clinician driven disparities.
As noted earlier, the sample size before exclusions included 417 patients, 235
(56.4%) Caucasians and 182 (43.6%) Black/African Americans individuals who had a
least three office visits within the 18 month time frame. Of patients excluded because
LDL was under control, 34.5% were Caucasian and 12.1% were Black/African
American (see Appendix A). Therefore, more Caucasians were included in the initial
sample (417) since they came in more frequently for health care and more were
excluded because their LDLs were more often under control.
The study sample (N=75) was not representative of the original query or the
clinic population. The study sample included more Black/African American patients
than in the clinic population or the query (N=417). The study sample of Caucasions
was representative of the clinic population.
This information suggests that at the start of the study the sample was a fairly
homogenous group and was perhaps not representative of the entire patient population
at the clinic, particularly Black/African Americans. The findings may have changed if
the sample included Blacks/African Americans who did not come in to be seen and did
not have lab work drawn in a timely manner.
There was not a significant difference between Caucasians and Black/African
Americans related to initiation of statins when LDL was out of control (Appendix I).
The same number of individuals of all races had LDLs that were out of control and on
a statin as those whose LDL was out of control and not on a statin. This table shows
appropriate management of patients who were on a statin and whose LDL was out of
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control. Medications were increased 46.4% of the time and changed 21.4% of the
time. Of note, medications were more frequently increased in African Americans who
were on medications but whose LDLs were out of control. If health care disparities
were occurring at the clinic, one would expect medications would be increased less
frequently in this group when compared to Caucasions.) Conversely, half of all three
groups who had LDLs above goal were not started on medications, regardless of race.
LDL findings.
Patients with suboptimally controlled LDLs at the beginning of the study’s
time frame were more likely to be female (43%), privately insured (68%), and married
(43%). There were more Caucasians who had LDL under control at the beginning of
the study; these individuals had slightly poorer control at the end of the study. This
finding is of interest since individuals with higher socioeconomic status often benefit
from environment factors that would help control LDLs. This may be related to the
urban location of the clinic and, again, could not be generalized to other clinics.
Patients whose LDL was out of control at the beginning of the study (Appendix J)
were more likely to be female, privately insured, and married. Patients whose LDL
was under control at the end of the study’s time period were more likely to be older
(60 vs. 54 years of age) and female (Appendix K); female patients were more
successful at getting their LDLs under control given they were more likely to be out of
control one year prior.
Inclusion in this study required at least two LDLs and a minimum of three
office visits between 1/1/2008 and 6/30/2009. LDL values may have been obtained
anywhere during this time frame; many individuals had more than two LDLs values
and fourteen patients had more than the average 5 office visits (Appendix L). Both of
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these factors may be skewing the findings. 14 patients in the study came in for more
than 5 office visits; one patient came in ten times. These factors may also be skewing
data related to LDL measurement.
Medication management related to LDL values was tracked during the study.
The patients were divided into two groups, those who were and were not on
medication when LDL was measured at baseline (see Appendix L) during the study.
Of the 60.7% of patients whose LDL was out of control at first measurement, 78.6%
were still out of control by the third office visit and 39.3% were still out of control by
the fourth office visit. At the beginning of the study, the largest group of patients had
LDLs that were out of control and were not on medications (37.3%). This may be
related to the degree by which the LDL was out of control. Table 2 illustrates LDL
values all of which are considered out of control with the exception of the first
reading for patient 1.

Table 2
Examples of elevated LDL values over time
Patient 1

70

115

127

Patient 2

144

134

148

121

126

115
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Only 40% of patients in the study whose LDL was suboptimally controlled at
baseline and who were not on a statin at the beginning of the study were started on a
statin. However, of those patients who were on a medication but whose LDL was out
of control at baseline, almost 50% had an increase in dose and 21% had a change in
medication.
According to current D5 measurements, LDLs should be under 100. As
illustrated above, some patients had LDL values that were close to but above 100.
Clinicians often choose not to start or increase medications in patients when values are
close to goal. However, it is recommended patients with diabetes who also have
certain comorbidities including hypertension and/or coronary atherosclerosis should
maintain an LDL at or below 70.
The majority of patients came in to the clinic three to five times during the time
frame of the study and had two or more LDL values drawn during the approximately
12 months when the person’s care was tracked. At each of these data points, the
patient was determined to have LDLs that are in or out of control and if the individual
was taking a statin. LDL value and use of medications could change over the time of
data collection. Therefore, an individual whose LDL was under control at time one
may or may not have been under control by the end of the study.
It is notable that at point one in data collection, 56/75 or 75% of individuals
had LDL values above goal. Of these 56 individuals, 50% of individuals were not on
a medication and 50% were on medication. At the end of the study, 28% of patients
had a LDL at goal, 70% were on statins; 49% of the patients who were not at goal
were not on a statin.
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Race/ethnicity.
There is discussion regarding the definition of race and ethnicity and use of
these terms when discussing health care disparities. It is often social rather than
genetic factors that underlie the racial gap in society and in health care. Hebert (2008)
lists the differing definitions used by various organizations including the Agency for
Healthcare Research and Quality (AHRQ), the IOM, and the World Health
Organization (WHO). This author adopts Hebert’s definition of race as a “social
construct based on phenotype . . . . [the observable, physical expression of genetic and
environmentally determined characteristics] . . . . and as a marker for exposure to
social factors that can influence health including socioeconomic position, lifestyle
habits, and use of health care (p. 375).” He defines ethnicity as another social
construct that is based on a shared culture, ancestry, language, religion, and traditions.
Given the overlap in these definitions, Hebert recommends the use of the blended
term, race/ethnicity.
This study depended on race/ethnicity information supplied by the patient
(usually over the telephone) when registering at the clinic for an initial appointment.
This health care system currently provides reception staff with a brief script to assist in
gathering race/ethnicity information or answering patient questions regarding the need
for this information. The fact that this health care system requests and records
race/ethnicity is a more forward-thinking approach than some institutions which have
not yet begun to collect information regarding race/ethnicity. Without collection of
data regarding race/ethnicity, it might be assumed that there are no health care
disparities. Information regarding race/ethnicity is necessary to develop statistical
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models that seek to measure disparities in care (Hasnain-Wynia, Pierce, Haque,
Hedges Greising, Prince, & Sabin, 2007).
CAM/patient preference.
Only one person tried CAMs at any point throughout the entire study
(Appendix I). Ten of the 28 individuals with LDLs out of control at baseline and not
on any medications had expressed a preference to try something other than statins; 5
were Caucasian, 4 were African American, and 1 was Eastern African (Appendix M).
Economic issues.
Three patients whose LDLs were in control changed medications due to
financial concerns or had changes in insurance that required a change in medication
(Appendix J). In all three cases, clinicians responded in an appropriate manner, e.g.
referral to the clinic social worker, utilization of a low cost drug plan, or use of a
medications on the patients pharmaceutical formulary. It may be that most clinicians
chose initial medications that are more economical for the patient so very few patients
have concerns regarding the high cost of medications. Cost was determined to be
more of an issue for African American patients 37.5% of the time than for Caucasians
or Eastern Africans.
Side effects.
Side effects of statins may include myalgias, muscle weakness persisting for
more than two days, nausea, abdominal pain, yellowing of skin and eyes. Laboratory
values used to assess medication side effects of statins include a creatinine kinase and
alanine transaminase. In this study, only six (8%) patients had side effects of the statin
prescribed (Appendix N).
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Adherence issues.
Medication adherence issues were identified in 8 (10.7%) of all patients
included in the study; this issue was most evident among Eastern Africans (60%).
However, the sample number of Eastern Africans was quite small and included only
nine individuals.
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Chapter 5
Discussion of Findings
This study did not demonstrate the presence of clinician driven disparities but
instead showed the need for improved care in the management of LDLs of all patients
with diabetes regardless of race.
Inclusion/exclusion criteria indicated more Black/African Americans were
included due to poor control of LDLs, yet more of these individuals were excluded
because of inadequate lab data. Although the inclusion/exclusion criteria resulted in
approximately the same percentage as Black/African Americans and Caucasians, the
resulting study sample of 75 was a fairly homogenous group of patients who came in
for lab testing and office visits on a regular basis. Additional information regarding
health care disparities might be obtained by taking a closer look at the individuals who
were excluded as part of the study design. In order to increase the sample size,
especially the numbers of African Americans and Eastern Africans, it may be
necessary to broaden the scope of the study to include other clinics within or outside
this health care system.
The researcher recommends several system changes related to the methodology
of the study. The study tool should be streamlined and validated. This study tool
extracted data at several different points in time during the time frame of the study.
While some conclusions can be drawn from actions at each of these points in time, it
would be most informative to use a tool that tracks the progression of clinician actions
by analyzing the sequence of actions taken at each visit.
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A large portion of time was spent during the chart review as the researcher
searched the electronic medical record for information to allow the separation of
African American and Eastern African patients. The researcher recommends the use
of a demographic tool with granular data reflecting the race/ethnicity of individuals
who are currently residence of the community. The tool should also contain an open
“other” category for individuals whose race/ethnicity is not reflected in the drop down
menu. This “other” information could be used to adjust the demographic tool as
demographics of the community change Collection of this information has become
more important with the increasing diversity of patients seen with in the health care
system, each group with its unique psychosocial perspective and approach to lifestyle
changes, particularly diet and exercise.
It may be helpful to have experts in the management of LDL levels of patients
with diabetes review the most current best practice recommendations in care of these
patients. The health care system where the study took place uses the Plan-Do-CheckAct approach based on Deming’s Wheel (1986) which is helpful to identify and assist
in management of gaps in the use of protocols and recommendations regarding models
of care.
It is important to have BMI measures that are accurate and obtained in a
consistent manner. In addition, as recommended in the writings of Dr. Edward
Wagner, the assignment of diabetes registry management to one individual instead of
individual clinician/nurse teams may facilitate increased numbers of patients seen at
the clinic.
Patient preference had a minimal effect on management of LDLs in this study.
Most patients were willing to use medications for management of LDL and did not
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object to increases in dose. Very few patients experienced side effects of statins or
voiced a preference regarding treatment including the wish for a trial of lifestyle
changes or use of complimentary alternative medicine. Only a small number of
patients expressed concern regarding the cost of medications. However, large
numbers of patients had LDLs that were uncontrolled and should have been started on
statins; others were taking a statin but the dose needed to be adjusted to bring LDL
values to recommended levels.
This project was an extremely valuable learning experience. The project
confirmed the writer’s interest in research in the clinical setting and the opportunity to
expand knowledge personally and to share and discuss the study findings with other
individuals and health care systems. The writer has a clearer understanding of the
research process including the importance of IRB approval and the ethical demands of
research. This study required the assistance and support of many individuals within
and outside of the health care system including a research assistant, statistician, and
physician informatics specialist.
Conclusions/Recommendations Related to the Need for System Changes
This study showed a need for several system changes to improve care of all
patients with diabetes who have elevated LDLs. A work team should be employed to
identify and manage gaps in clinician use of protocols. The use of experts in evidence
based practice regarding diabetes management and a change in focus of clinician
education and continuing education toward improved management of chronic diseases
would be helpful.
The study results did not show clinician driven disparities. However, results
showed the need for system changes designed with a vision of equity in health care
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that is aligned with the goal of improved patient outcomes for individuals of all races
and ethnicities who have diabetes. In addition, results may determine if the study tool
is an appropriate tool for measurement of clinician actions in other areas of health care
research.
A system change is needed to improve adherence regarding minimal follow up
visits and lab work. A recommendation is to assign one care coordinator within the
clinic the responsibility of using the diabetes registry to contact patients who have not
been seen in a timely manner or who need lab work. This fits well with the model of
the health care home, a system change currenting used in several of this health care
system’s primary care sites that has been shown to improve patient care, outcomes,
and clinician satisfaction in care of patients with chronic illnesses. Health care home
assigns patients to one of four tiers and reimburses the health care system depending
on complexity of care. Level of complexity is determined using the number and type
of diagnosed illnesses for each patient, the need for translation services for the patient
and/or caregiver, and the presence of mental health issues. Health care home
reimbursement varies from tier 1 (least complex) of approximately $10 to tier 4 (most
complex) of approximately $60 per patient per month.
Accurate demographics and a complete patient problem list are key to
receiving the highest possible reimbursement from third party payers (personal
communications with director of health support and contractor for implementation of
Epic in the clinical setting, October, 2010). Even with the upcoming transition to
Epic, clinicians will be required to enter patient diagnoses on the problem list. The
importance of population of the problem list will be stressed to clinicians during the
roll out of Epic. It is predicted Epic will allow improved data extraction from the
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electronic medical records; this change should improved efficiency and accuracy for
health care research with a combined goal of optimal patient outcomes and responsible
stewardship of health care dollars.
The data collection tool gathered information from the patient problem list
regarding comorbidities and complications related to diabetes and LDL management.
Hypertension is one of these comorbidities and complicates treatment of patients with
diabetes. Accurate information on the patient problem list is important since the
recommended LDL goal of individuals with comorbidities is less than 70 mg/dL rather
than a goal of 99 mg/dL or below in individuals with diabetes who do not have one of
these comorbidites or complications.
In this study, more specific information regarding Black/African American
categories would have facilitated efficiency and accuracy in the determination of either
African American or Eastern African race/ethnicity. A system change working toward
use of an improved race/ethnicity demographic tool with a drop down feature under
each race of more granular data information of all patients is necessary. Legal action
at the national level mandating consistency in collection of more complete information
among government agencies would have an impact would have an effect on data
collection at the local level. It may be helpful to conduct a public health campaign,
similar to that of the Census Bureau, informing patients of the change in collection of
race/ethnicity information as an effort to provide improved health care to all who live
in the community.
A systems change could focus on obtaining consistently accurate BMI
information. Many patients are measured with significantly different types of
footwear and outer garments which vary from day to day and from season to season.
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Although this study did not show health care disparities, this health care system may
want to further explore issues related to discordance between health care providers and
patients. According to Chen, Fryer, Phillips, Wilson, and Joseph (2005), only 22% of African
Americans perferred an African American clinician; 65% had no preference. Caucasians
preferred a Caucasian clinician 13% of the time; 75% had no preference. Of those patients
who had a preference, those whose preferences were met more often rated their care as
excellent. It is acknowledged patients may be guessing regarding the race/ethnicity of their
clinician similar to guesses that may occur when the patient registers at this clinic. At this
time, the role of the patients’ beliefs and preferences as contributing factors related to health
care disparities are unclear. Although discordant patient-clinician race may not affect quality
of care, having a concordant race provider might incentivize patients to follow up on care
recommendations. According to the authors, these findings are consistent with previous
research and, based on the findings, “the solutions for racial and ethnic disparities in health
will need to go beyond increasing the number of minority physicians and attempting to teach
cultural competence; rather, addressing discrimination in the health care system, increasing
access to minority physicians, and improving the ways for patients to choose physicians may
be more potent options for reducing racial disparities” (p. 142).
Limitations of the Study
The findings of this study are not generalizable to other clinics within this
health care system or to other health care systems. The diabetes assessment tool was
developed by the researcher and has not been validated.
Sample size was quite small which limited the ability to capture significant differences
between Black/African Americans and Caucasians as well as affecting the reliability and
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generalizability of the findings. BMI measurements and patient problem lists are accepted
with the understanding there are concerns regarding accuracy and completeness.
The reseacher, a nurse practitioner familiar with LDL management in care of
patients with diabetes and who has an understanding of the medical record, was solely
responsible for the chart review and data collection. Given a larger budget, additional
clinicians could participate in the chart review allowing for comparison of findings.
Dissemenation
This information will be presented to the researcher’s advisor and professors at St.
Catherine University and key stakeholders at the health care system where the study took
place. Decisions regarding poster presentation and national meetings and publication will be
made after completion of the study.
Implications for nursing
This study supports the role of the doctorally prepared nurse as being aware of
concerns in the practice setting and using leadership skills to incorporate evidence based
practice guidelines and research to make system changes that improve patient care and
outcomes in the clinic, community, and nation. Working along with a Ph.D. prepared
statistician illustrated the benefits of combining efforts with a D.N.P. in research and a better
understanding of specific patient care needs.
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Appendix A
Sample Size, Inclusion and Exclusion
Criteria

Cauca
-sian
Inclusion Criteria, n (% of initial
sample)
Had 3 office visits from Jan 08-June09
Exclusion Criteria, n (% of initial
sample)
LDLs under control throughout the study

Inadequate information on LDLs

Lab visits were in 2009, but after June
30th
Only had 1 LDL during study’s
timeframe
No LDL lab visits during study’s
timeframe
Never had an LDL
Insurance Issues
Unclear information re AA or EA
DM care through endocrinology
AA/BL but not AA or EA
<3 office visits within during study’s
timeframe
Total Excluded, n (% of initial sample)
Final Sample, n (% of final sample)

African
Americ
an

East
Afric
an

Blacks
:
AA+E
A

Tot
al

235
56.4%

182
43.6%

417

81

22

34.5%
57

12.1%
57

24.3%

31.3%

103
24.7
%
114
27.3
%

27

20

47

9

14

23

20
1
28
NA
17

22
1
8
31
5
15

42
2
36
31
21
15

9
194
82.6%
41
54.7%

3
148
81.3%
34
45.3%

12
342

72

30

19

15

75
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Appendix B
Registration Options: Eastern African Countries and Languages
Country

Language Options

Burundi

French, Swahili

Djibouti

Arabic, Somali, French

Eritrea

Tigrinya, Arabic

Ethiopia

Amharic, Somali

Kenya

Swahili, Arabic, Somali

Malawi

Primary non-English language not offered

Mozambique

Swahili

Rwanda

French

Somalia

Somalia, Swahili, Arabic

Tanzania

Swahili

Uganda

Swahili

Note. Does not included languages/dialects spoken but not included as option on clinic/system list.
From http://www.cdc.gov/2008.
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Appendix C
Insurances Accepted at Clinic
Government
Medicaid

Private
Aetna

BCBS PMAP/MN Care

Americas PPO/TPA

HP PMAP/MN Care

BCBS

Medica PMAP/MNCare

BCBS Mgd Care

Medicaid/MNCare/Champus

HP Insured

Ucare PMAP/MNCare

HP Open Access Insured

Medicare

HPOpen Access Self Insured

BCBS MedicareBlue PPO

HP Out of Network

BCBS MCHO/SNP Secure Blue

HP self Insured

BCBS Vantage Blue Cost

Industrial

HP 65+ CAP

Medica Choice

HP Freedom 65+ Cost

Medica Elect

HP MSHO

Medica SelectCare

Medica MSHO

No CF Grouping

Medica Seniors Cost

Non Contracted

Medicare FFS

Other Commerical

Medicare Private FFS

Patient Choice

Ucare Seniors

PrePay
Preferred One CHP
Preferred One PPO
Preferred One Specified
Self Pay
Special Processing
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Appendix D
DIABETES CHART AUDIT TOOL
Zip Code: ______________
Res#

PROVIDER INITIALS

Age

Gender

 M
 F

No. MD visits/time frame:

Contacts w/HSN:

No. known failed appts:

Contacts w/IDC:

Race/Eth

 Cauc
Payer
 AfAm
 EastAf
Marital Status D M P S U W X
Interpreter /Language:
/
Process Care Measures
Comorbidities/Complications
/
/
- /
/
401. 402. 403. 404. 405. 414.
/

 Gvmt

/
/

- Ht:
-

STARTING WITH EARLIEST CHOL DURING ABOVE TIME FRAME
st

Date of 1 OV related to Process Care Measures :
/ ____/______
Date of Applicable Cholf:_______________ (Circle one: LDL <100; LDL ≥ 100)
 Y  N Side effects, ____________
 Y  N Lifestyle coaching only
 Y  N CAM
 Y  N Start statining agent
 Y  N Currently on statining agent
 Y  N Statining agent discontinued by clinician
 Y  N Increase statining agent
 Y  N Change statining agent
 Y  N Patient preference considered
 Y  N Cost/insurance identified as an issue
 Y  N Appropriate action taken
 Y  N Advised repeat cholf or F/U visit in : ≤ 3 mos. ≤ 1 yr.
 Y  N Measurement related to start/increase of medication
 Y  N Therapeutic delay in Rx mgmt. (e.g.: Etoh)
 Y  N Adherence issue related to cholf mgmt identified
Date of Visit:_________________
Date of Related LDL:________________
 Y  N LDL at goal? (most recent cholf-PREVIOUS/SAME DAY/p OV)
 Y  N Side effects, ____________
 Y  N Lifestyle coaching only (no medications)
 Y  N CAM
 Y  N Start lipid lowering agent
 Y  N Currently on lipid lowering agent
 Y  N Increase lipid lowering agent
 Y  N Change lipid lowering agent
 Y  N Patient preference considered
 Y  N Cost/insurance identified as an issue
 Y  N Appropriate action taken
 Y  N Advised repeat cholf or F/U visit : ≤ 3 mos. ≤ 1 yr.
 Y  N Therapeutic delay in Rx mgmt. (eg: Etoh)
 Y  N Adherence issue related to cholf mgmt identified
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 Private

Wt:
Wt:

BMI:
BMI:
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Date of Visit:_________________
Date of Related LDL:________________
 Y  N LDL at goal? (most recent cholf- PREVIOUS/SAME DAY/p OV)  NA ___________
 Y  N Side effects, ____________
 Y  N Lifestyle coaching only (no medications)
 Y  N CAM
 Y  N Start lipid lowering agent
 Y  N Currently on lipid lowering agent
 Y  N Lipid lowering agent discontinued by clinician
 Y  N Increase lipid lowering agent
 Y  N Change lipid lowering agent
 Y  N Patient preference considered
 Y  N Cost/insurance identified as an issue
 Y  N Appropriate action taken
 Y  N Advise repeat cholf or F/U visit in : ≤ 3 mos. ≤ 1 yr.
 Y  N Therapeutic delay in Rx mgmt. (e.g.: Etoh)
 Y  N Adherence issue related to cholf mgmt identified
Date of Visit:_________________
Date of Related LDL:________________
 Y  N LDL at goal? (most recent cholf PREVIOUS/SAME DAY/p OV )  NA ___________
 Y  N Elevated LFTs, CPK, myalgia, ____________
 Y  N Lifestyle coaching only (no medications)
 Y  N CAM
 Y  N Start lipid lowering agent
 Y  N Currently on lipid lowering agent
 Y  N Lipid lowering agent discontinued by clinician
 Y  N Increase lipid lowering agent
 Y  N Change lipid lowering agent
 Y  N Patient preference considered
 Y  N Cost/insurance identified as an issue
 Y  N Appropriate action taken
 Y  N Advised repeat cholf or F/U visit: ≤ 3 mos. ≤ 1 yr.  NA ?
 Y  N Therapeutic delay in Rx mgmt. (e.g.: Etoh)
 Y  N Adherence issue related to cholf mgmt identified
Date of Visit:_________________
Date of Related LDL:________________
 Y  N LDL at goal? (most recent cholf PREVIOUS/SAME DAY/p OV)  NA ___________
 Y  N Side effects, ____________
 Y  N Lifestyle coaching only (no medications)
 Y  N CAM
 Y  N Start lipid lowering agent
 Y  N Currently on lipid lowering agent
 Y  N Lipid lowering agent discontinued by clinician
 Y  N Increase lipid lowering agent
 Y  N Change lipid lowering agent
 Y  N Patient preference considered
 Y  N Cost/insurance identified as an issue
 Y  N Appropriate action taken
 Y  N Advised repeat cholf or F/U visit in : ≤ 3 mos. ≤ 1 yr.
 Y  N Therapeutic delay in Rx mgmt. (e.g.: Etoh )
 Y  N Adherence issue related to cholf mgmt identified

Appendix D, Continued

61
Initial/Date:
Total chol
Trigs
Ratio
HDL
LDL
A1C
 YN

Deceased

ADDITIONAL INFORMATION/NOTES:

Date:

Date:

Date:

Date:
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Appendix E
Demographic Characteristics by Race

Sample Size (%)
Average Age (SD)
Female (%)
Privately Insured (%)
Married (%)
Interpreter (%) (n=7)
• Language (%)
(n=7)

Caucasian
41 (54.7%)
56.7 (10.5)
15 (36.6%)
30 (73.2%) *
17 (41.5%)

Race
African American
19 (25.3%)
55.1 (11.3)
12 (63.2%) *
9 (47.4%)
6 (31.6%)

•

•

East African
15 (20%)
53.7 (8.8)
1 (6.7%)
7 (46.7%)
5 (33.3%)
7/15 (46.7%)
•

Oromo 2/7

Somali 5/7
Notes: SD = Standard Deviation
* Significant at the 0.05 level

Total Sample
75
55.7 (10.3)
28 (37.3%)
46 (61.3%)
28 (37.3%)
7 (9.3%)
•

7(9.3%)
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Appendix F
Demographic Characteristics by Payer
Payer
Government
Private
29 (38.7%)
46 (61.3%)
Sample Size (%)
57 (12.4)
55 (8.9)
Mean Age (SD)
12 (41.4%)
16 (34.8%)
Female
5
(17.2%)
23 (50%)
Married
4 (13.8%)
3(6.5%)
Interpreter
Oromo 2/3
Language
Somali 4/4
Somali 1/3
Notes: SD = Standard Deviation
* Significant at the 0.05 level
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Appendix G
BMI and Obesity Measures by Race
Race
African
Caucasian
American
41
19
Sample Size (%)

East African
15

Total
Sample
75

Calendar Year 2008
BMI - 2008
40
16
9
Sample Size
65
34.6
35.2
27.3 *
Average BMI
Standard
5.77
5.51
3.72
Deviation
21.6, 48.0 27.0, 45.9
23.0, 33.0
Range
Obesity - 2008
1
0
3
BMI<25
4
2.5%
0.0%
33.3%
6.2%
Percent
7
3
4
BMI>=25
14
17.5%
18.8%
44.4%
21.5%
Percent
32
13
2
BMI>=30
47
80.0%
81.3%
22.2%
*
72.3%
Percent
Calendar Year 2009
BMI - 2009
40
15
9
Sample Size
64
34.2
35.7
27.9 *
Average BMI
Standard
6.0
5.94
3.22
Deviation
22.4, 48.0 26.3, 47.3
23.9, 32.9
Range
Obesity - 2009
3
0
3
BMI<25
6
7.5%
0.0%
33.3%
9.4%
Percent
6
3
4
BMI>=25
13
15.0%
20.0%
44.4%
20.3%
Percent
31
12
2
BMI>=30
45
77.5%
80.0%
22.2% *
70.3%
Percent
Notes: BMI = Body Mass Index
* Differences between East Africans and Caucasians, and East Africans and African Americans were
significant at the 0.05 level
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Appendix H
Demographic Characteristics by Obesity Measures, 2008
BMI
Missing
Total
<25
25+
30+
Sample
Data
4
14
47
Sample Size
10
75
Race
53.3
55.4
56.6
Age
53.1
7.4
9.3
10.7
Standard Deviation
11.8
1
3
22
Female
2
28
25.0%
21.4% 46.8% * 20.0%
37.3%
Percent
2
9
32
Private Insurance
3
46
50.0%
64.3%
68.1%
30.0%
61.3%
Percent
2
5
17
4
Married
28
50.0%
35.7%
36.2%
40.0%
37.3%
Percent
1
3
1
2
Interpreter
7
25.0%
21.4%
2.1% *
20.0%
9.3%
Percent
Language
Oromo 2/7
1
1
0
7
Somali 5/7
2
1
2
113.8
118.0
148.0 ** 115.6
116.5
Last LDL Values
116
113
Median
137
111
114
42.0
23.8
29.4
Standard Deviation
25.5
29.1
% Last LDL at Goal
0
3
16
2
21
0.0%
21.4%
34.0%
20.0%
28.0%
Percent
Notes: BMI = Body Mass Index
* Differences between BMI groups 30+ and 25+, and BMI groups 30+ and <25 were significant at the
0.05 level
** Differences between BMI groups <25 and 25+, and BMI groups <25 and 30+ were significant at the
0.05 level
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Appendix I
Actions Taken During the Year Given Baseline Status on LDLs and Medications
Baseline
LDL<100
LDL>=100
Sample Size
19
56
On Meds
No Meds
On Meds
No Meds
Group
1
2
3
4
Sample Size
15
4
28
28
Lifestyle
0
2 (50%)
0
14 (50%)
Nutritional/CAM
0
0
0
1 (3.6%)
11
Start Medications
5 (33.3%)
0
2 (7.1%)
(39.3%)
Discontinued Meds
2 (13.3%)
0
1 (3.6%)
0
13
Increased Dose of Meds
3 (20%)
0
(46.4%)
4 (14.3%)
Changed Meds
3 (20%)
0
6 (21.4%)
1 (3.6%)
Caucasian
On Meds
No Meds
On Meds
No Meds
Sample Size
10
3
14
14
Lifestyle
0
1 (33.3%)
0
8 (57.1%)
Start Medications
2 (20%)
0
0
4 (28.6%)
Discontinued Meds
1 (10%)
0
1 (7.1%)
0
Increased Meds
3 (30%)
0
6 (42.9%) 2 (14.3%)
Changed Meds
1 (10%)
0
2 (14.3%)
0
African American
On Meds
No Meds
On Meds
No Meds
Sample Size
2
1
8
8
Lifestyle
0
1 (100%)
0
5 (62.5%)
Nutritional/CAM
0
0
0
1 (12.5%)
Start Medications
0
0
0
3 (37.5%)
Discontinued Meds
1 (50%)
0
0
0
Increased Meds
0
0
5 (62.5%) 1 (12.5%)
Changed Meds
1 (50%)
0
4 (50%)
0
East African
Sample Size
3
0
6
6
Lifestyle
0
0
1 (16.7%)
Start Medications
3 (100%)
2 (33.3%) 4 (66.7%)
Discontinued Meds
0
0
0
Increased Meds
0
2 (33.3%) 1 (16.7%)
Changed Meds
1 (33.3%)
0
1 (16.7%)
All Blacks
Sample Size
5
1
14
14
Lifestyle
0
1 (100%)
0
6 (42.9%)
Start Medications
3 (60%)
0
2 (14.3%)
7 (50%)
Discontinued Meds
1 (20%)
0
0
0
Increased Meds
0
0
7 (50%)
2 (14.3%)
Changed Meds

2 (40%)

0

4 (28.6%)

1 (7.1%)

Total
75
Total
75
16 (21.3%)
1 (1.3%)
18 (24%)
3 (4.0%)
20 (26.7%)
10 (13.3%)
41
9 (22%)
6 (14.6%)
2 (4.9%)
11 (26.8%)
3 (7.3%)
19
6 (31.6%)
1 (5.3)
3 (15.8%)
1 (5.3%)
6 (31.6%)
5 (26.3%)
15
1 (6.7%)
9 (60%)
0
3 (20%)
2 (13.3%)
34
7 (20.6%)
12 (35.3%)
1 (2.9%)
9 (26.5%)
7 (20.6%)
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Appendix J
Demo Characteristics by LDL Under Control at Time One
LDL Not in
LDL in
Control
Control
LDL>=100
LDL<100
Sample Size (%)
56
19
Race (%)
Caucasian
28 (50%)
13 (68.4%) *
African American
16 (28.6%)
3 (15.8%)
East African
12 (21.4%)
3 (15.8%)
Average Age (SD)
54.8 (10.2)
58.4 (10.7)
Female (%)
24 (42.9%) *
4 (21.1%) *
Privately Insured (%)
38 (67.9%)
8 (42.1%) *
Married (%)
24 (42.9%)
4 (21.1%) *
Interpreter (%) (n=7)
6 (10.7%)
1 (5.3%)
Oromo 1/6
Oromo 1/1
Language (%) (n=7)
Somali 5/6
Notes: SD = Standard Deviation
* Differences significant at 0.05 level
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Appendix K
Demo Characteristics by LDL Under Control Within a Year
LDL Not in
LDL in
Control
Control
LDL>=100
LDL<100
Sample Size (%)
54
21
Race (%)
Caucasian
29 (53.7%)
12 (57.1%)
African American
12 (22.2%)
7 (33.3%)
East African
13 (24.1%)
2 (9.5%)
Average Age (SD)
53.9 (10.6)
60.3 (8.3) *
Female (%)
17 (31.5%)
11 (52.4%) *
Privately Insured (%)
31 (57.4%)
15 (71.4%)
Married (%)
21 (38.9%)
7 (33.3%)
Interpreter (%) (n=7)
6 (11.1%)
1 (4.8%)
Oromo 2/6
Language (%) (n=7)
Somali 4/6
Somali 1/1
Notes: SD = Standard Deviation
* Differences significant at 0.05 level
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Appendix L
Number Actions Taken Given Baseline Status on LDLs and Medications by Time Period
Baseline
LDL<100
LDL>=100
Sample Size
19
56
No
On
No
On Meds
Meds
Meds
Meds
Group
1
2
3
4
Sample Size
15
4
28
28

T1

T2

T3

T4

# Actions Taken
In Each Time
Period
At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions

% No
Actio
n
15
13
2

86.7%
13.3%

% No
Action
4
4

% No
Action

% No
Action

100%

28
17
10
1
4
4

60.7%
35.7%
3.6%
14.3%
100%

28
13
15

46.4%
53.6%

3
2
1

10.7%
66.7%
33.3%

11
10
1

73.3%
90.9%
9.1%

2
2

50.0%
100%

4
2
2

26.7%
50.0%
50.0%

2
2

50.0%
100%

24
20
4

85.7%
83.3%
16.7%

25
15
10

89.3%
60.0%
40.0%

11
8
3

73.3%
72.7%
27.3%

1
1

25.0%
100%

6
6

21.4%
100%

4
4

14.3%
100%

4
3
1

26.7%
75.0%
25.0%

3
1
2

75.0%
33.3%
66.7%

22
17
5

78.6%
77.3%
22.7%

24
15
9

85.7%
62.5%
37.5%

6
6

40.0%
100%

8
8

28.6%
100%

3
3

10.7%
100%

6
4
1
1

40.0%
66.7%
16.7%
16.7%

11
11

39.3%
100%

11
6
5

39.3%
54.5%
45.5%

1

25.0%

1

100%
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T6

T7

T8

T9

did not have 4
visits
At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
did not have 5
visits
At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
did not have 6
visits
At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
did not have 7
visits
At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
did not have 8
visits
At Goal
0 actions

3
5
5

1
1

33.3%
100%
0.0%
0.0%
6.7%
100%
0.0%
0.0%

9
4
4

26.7%
100%

2
2

13.3%
100%

9
4
4

11
2
2

2
1
1

11
1
1

3
1
1

25.0%
100%

9
3
3

6
5
1

3

4
26.7%
100%

4

10.7%
100%
0.0%
0.0%
21.4%
83.3%
16.7%
0.0%

14.3%
100%

23
1
1

2
1
1

7.1%
50.0%
50.0%

1
0
1

3.6%
100%
0.0%
0.0%
3.6%
0.0%
100%

22
2
2

7.1%
100%

26
1
1

3.6%
100%

2
2

7.1%
100%

13.3%
100%

7.1%
100%

13.3%
50.0%
50.0%

1
0
1

3.6%
0.0%
100%

6.7%
100%

3
2
1

7.1%
100%
0.0%
0.0%
10.7%
66.7%
33.3%
0.0%

19
4
4

24
2
2

4

14
2
2

25
1
1

27

1
0
1

27
3.6%
100%

3.6%
0.0%
100%
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1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
< 9 visits
T1
0

At Goal
0 actions
1 action
2 actions
Not at Goal
0 actions
1 action
2 actions
< 10 visits

1
0
1

6.7%
0.0%
100%

13

1
1

14

4

27

28

4

28

28

6.7%
100%
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Appendix M
Patient Issues During the Year Given Baseline Status on LDLs and Medications
Baseline
LDL<100
LDL>=100
Sample Size
19
56
On Meds No Meds On Meds
No Meds
Group
1
2
3
4
Sample Size
15
4
28
28
Patient Preferences
1 (6.7%)
0
1 (3.6% 10 (35.7%)
Cost
1 (6.7%)
0
5 (17.9%) 1 (3.6%)
Appropriate Action
1 (6.7%)
0
5 (17.9%)
0
Caucasian
Sample Size
10
3
14
14
Patient Preferences
0
0
0
5 (35.7%)
Cost
1 (10%)
0
2 (14.3%) 1 (7.1%)
Appropriate Action
1 (10%)
0
2 (14.3%)
0
African American
Sample Size
2
1
8
8
Patient Preferences
0
0
0
4 (50%)
Cost
0
0
3 (37.5%)
0
Appropriate Action
0
0
3 (37.5%)
0
East African
Sample Size
3
0
6
6
Patient Preferences
1 (33.3%)
1 (16.7%) 1 (16.7%)
Cost
0
0
0
Appropriate Action
0
0
0
All Blacks
Sample Size
5
1
14
14
Patient Preferences
1 (20%)
0
1 (7.1%) 5 (35.7%)
Cost
0
0
3 (21.4%)
0
Appropriate Action
0
0
3 (21.4%)
0

Total
75
Total
75
12 (16%)
7 (9.3%)
6 (8%)
41
5 (12.2%)
4 (9.8%)
3 (7.3%)
19
4 (21.1%)
3 (15.8%)
3 (15.8%)
15
3 (20%)
0
0
34
7 (20.6%)
3 (8.3%)
3 (8.3%)
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Appendix N
Follow-up Issues During the Year Given Baseline Status on LDLs and Medications
Baseline
LDL<100
LDL>=100
Sample Size
19
56
On Meds
No Meds
On Meds
No Meds
Group
1
2
3
4
Sample Size
15
4
28
28
Repeat Cholesterol Ck
12 (80%)
2 (50%)
24 (85.7%) 25 (89.3%)
Therapeutic Delay in Rx
1 (6.7%)
0
3 (10.7%)
4 (14.3%)
Adherence Issues
3 (20%)
0
10 (35.7%) 5 (17.9%)
Elevated Labs (re Group 2)
3 (20%)
0
3 (10.7%)
0
Caucasian
Sample Size
10
3
14
14
Repeat Cholesterol Ck
7 (70%)
1 (33.3%) 13 (92.9%) 11 (78.6%)
Therapeutic Delay in Rx
0
0
1 (7.1%)
2 (14.3%)
Adherence Issues
1 (10%)
0
2 (14.3%)
1 (7.1%)
Elevated Labs (re Group 2)
1 (10%)
0
0
0
African American
Sample Size
2
1
8
8
Repeat Cholesterol Ck
2 (100.0%) 1 (100.0%) 7 (87.5%) 8 (100.0%)
Therapeutic Delay in Rx
0
0
2 (25%)
1 (12.5%)
Adherence Issues
0
0
3 (37.5%)
2 (25%)
Elevated Labs (re Group 2)
1 (50%)
0
2 (25%)
0
East African
Sample Size
3
0
6
6
Repeat Cholesterol Ck
3 (100.0%)
4 (66.7%) 6 (100.0%)
Therapeutic Delay in Rx
1 (33.3%)
0
1 (16.7%)
Adherence Issues
2 (66.7%)
5 (83.3%)
2 (33.3%)
Elevated Labs (re Group 2) 1 (33.3%)
1 (16.7%)
0
All Blacks
Sample Size
5
1
14
14
Repeat Cholesterol Ck
5 (100.0%) 1 (100.0%) 11 (78.6%) 14 (100.0%)
Therapeutic Delay in Rx
1 (20%)
0
2 (14.3%)
2 (14.3%)
Adherence Issues
2 (40%)
0
8 (57.1%)
4 (28.6%)
Elevated Labs (re Group 2)
2 (40%)
0
3 (21.4%)
0

Total
75
Total
75
63 (84%)
8 (10.7%)
18 (24%)
6 (8%)
41
32 (78%)
3 (7.3%)
4 (9.8%)
1 (2.4%)
19
18 (94.7%)
3 (15.8%)
5 (26.3%)
3 (15.8%)
15
13 (86.7%)
2 (13.3%)
9 (60%)
2 (13.3%)
34
31 (91.2%)
5 (14.7%)
14 (41.2%)
5 (14.7%)
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